SCHEMBL7770600

SCHEMBL7770600

CCCCCCCNCC(C)C

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.57
ALDH1A1 P00352 1/20 0.57
EPHX1 P07099 6/20 0.53
ANPEP P15144 1/20 0.50
ERAP2 Q6P179 1/20 0.50
ADH1B P00325 2/20 0.46
ADH1C P00326 2/20 0.46
ADH1A P07327 2/20 0.46
ADH4 P08319 2/20 0.46
ADH7 P40394 2/20 0.46
HRH4 Q9H3N8 2/20 0.43
HRH3 Q9Y5N1 2/20 0.43
S1PR2 O95136 5/20 0.42
S1PR4 O95977 5/20 0.42
S1PR1 P21453 5/20 0.42
S1PR3 Q99500 5/20 0.42
S1PR5 Q9H228 1/20 0.42
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14547329 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL30445370 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL10754488 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL7777003 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL3951483 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL6178364 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL23696536 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL8904740 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL11114390 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2
SCHEMBL9499039 1.00 TSHR (0.57) TSHRALDH1A1EPHX1ANPEPERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
WO-2023164057-A1 DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-08-31 WO disclosed
EP-3571205-B1 THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-08-30 EP disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed
CN-108602955-B Photocuring method, compound used in photocuring method, and composition 富士胶片和光纯药株式会社 2021-08-06 CN disclosed
CN-107848963-B Acid-resistant alkali-producing agent and/or radical-producing agent, and curable resin composition containing same 富士胶片和光纯药株式会社 2020-11-03 CN disclosed
CN-110678500-A Photo-or thermosetting method and curable resin composition 富士胶片和光纯药株式会社 2020-01-10 CN disclosed
EP-2924044-B1 PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO BEIJING SHUOBAI PHARMACEUTICAL CO LTD (CN) 2018-10-31 EP disclosed
EP-2759547-B1 PLATINUM COMPOUND HAVING AMINO- OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARATION METHOD THEREFOR, AND USE THEREOF BEIJING FSWELCOME TECH DEV CO LTD (CN) 2017-01-18 EP disclosed
WO-2016154622-A1 POLY(BETA-AMINO ESTER)-CO-POLYETHYLENE GLYCOL (PEG-PBAE-PEG) POLYMERS FOR GENE AND DRUG DELIVERY THE JOHNS HOPKINS UNIVERSITY (US) 2016-09-29 WO disclosed
US-20150368281-A1 Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD (CN) 2015-12-24 US disclosed
US-9175024-B2 Platinum compound having amino or alkylamino-containing succinic acid derivatives as leaving group, preparation method thereof, and use thereof BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2015-11-03 US disclosed
US-20140349985-A1 PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) 2014-11-27 US disclosed
EP-2759547-A1 PLATINUM COMPOUND HAVING AMINO- OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Fswelcome Technology Development Co., Ltd (CN) 2014-07-30 EP disclosed
US-20100040548-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS TECHFIELDS PHARMA CO., LTD (CN) 2010-02-18 US disclosed
EP-0838508-B1 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORP (JP) 2001-08-29 EP disclosed
US-5871572-A COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID SEIKO EPSON CORPORATION (JP) 1999-02-16 US disclosed
EP-0838508-A2 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORPORATION (JP) 1998-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885ALDH1A1 2776/4885EPHX1 1684/4885
US-20150368281-A1 Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino SLC7A1, ME3, SLC7A5 TSHR 4501/4885ALDH1A1 246/4885EPHX1 4211/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885ALDH1A1 2776/4885EPHX1 1684/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885ALDH1A1 2776/4885EPHX1 1684/4885
US-20100040548-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HAMP TSHR 4708/4885ALDH1A1 3310/4885EPHX1 308/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885ALDH1A1 2776/4885EPHX1 1684/4885
US-20140349985-A1 PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF SLC7A5, SLC43A1, SLC7A1 TSHR 4192/4885ALDH1A1 413/4885EPHX1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.